[go: up one dir, main page]

NO994481L - Sammensetninger og fremgangsmaater for redusering av okulaer hypertensjon - Google Patents

Sammensetninger og fremgangsmaater for redusering av okulaer hypertensjon

Info

Publication number
NO994481L
NO994481L NO994481A NO994481A NO994481L NO 994481 L NO994481 L NO 994481L NO 994481 A NO994481 A NO 994481A NO 994481 A NO994481 A NO 994481A NO 994481 L NO994481 L NO 994481L
Authority
NO
Norway
Prior art keywords
prostaglandin
compositions
methods
ocular hypertension
reducing ocular
Prior art date
Application number
NO994481A
Other languages
English (en)
Other versions
NO327713B1 (no
NO994481D0 (no
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994481(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO994481L publication Critical patent/NO994481L/no
Publication of NO994481D0 publication Critical patent/NO994481D0/no
Publication of NO327713B1 publication Critical patent/NO327713B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En forbedret øyesammensetning, som inkluderer prostaglandinaktive midler, som er særlig anvendelig til å sette ned det intraokulære trykket i forbindelse med glaucoma. Forbedringer i IOP reduseringseffektivitet, konserveringseffektivitet og reduserte konsentrasjoner av additiver oppnås ved anvendelse av de fremlagte sammensetningene som inkluderer et prostaglandinaktivt middel (f. eks. isopropyl unoproston, en metabolitt av en F-serie prostaglandin), i forbindelse med utvalgte ikke-ioniske surfaktanter, konserveirngsmidler og ikke-ioniske tonisitetsjusterende midler.
NO19994481A 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning NO327713B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (3)

Publication Number Publication Date
NO994481L true NO994481L (no) 1999-09-16
NO994481D0 NO994481D0 (no) 1999-09-16
NO327713B1 NO327713B1 (no) 2009-09-14

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994481A NO327713B1 (no) 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning

Country Status (32)

Country Link
EP (1) EP0969846B2 (no)
JP (2) JP4920124B2 (no)
KR (1) KR100555818B1 (no)
CN (1) CN1236775C (no)
AR (2) AR002194A1 (no)
AT (1) ATE257385T1 (no)
AU (1) AU738781B2 (no)
BR (2) BRPI9816218B1 (no)
CA (1) CA2280089C (no)
CL (1) CL2009001870A1 (no)
CO (1) CO4940427A1 (no)
CY (1) CY2526B1 (no)
CZ (1) CZ299833B6 (no)
DE (1) DE69820997T3 (no)
DK (1) DK0969846T4 (no)
EE (1) EE04091B1 (no)
ES (1) ES2214706T5 (no)
HU (1) HU228896B1 (no)
ID (1) ID22389A (no)
IL (1) IL131041A0 (no)
MY (1) MY122237A (no)
NO (1) NO327713B1 (no)
NZ (1) NZ337322A (no)
PE (1) PE61899A1 (no)
PL (1) PL197509B1 (no)
PT (1) PT969846E (no)
RU (1) RU2197970C2 (no)
SI (1) SI0969846T2 (no)
TW (1) TW527187B (no)
UA (1) UA63938C2 (no)
WO (1) WO1998041208A1 (no)
ZA (1) ZA982188B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
AU2001286210A1 (en) * 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
JP4881159B2 (ja) * 2004-03-18 2012-02-22 株式会社アールテック・ウエノ チアゾール誘導体を含む水性組成物
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
ES2460967T3 (es) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN104224704A (zh) * 2006-03-13 2014-12-24 株式会社·R-技术上野 水性组合物
KR101454674B1 (ko) * 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
JP2010508306A (ja) * 2006-10-31 2010-03-18 アルコン リサーチ， リミテッド 眼障害を治療するためのｐａｉ−１結合調節因子
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
MX2010003774A (es) * 2007-10-08 2010-04-27 Fovea Pharmaceuticals Sa Formulaciones oftalmicas acuosas.
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
KR101541303B1 (ko) * 2008-03-17 2015-08-03 알콘 리서치, 리미티드 보레이트-폴리올 복합체를 함유하는 수성 약학적 조성물
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PT2787969T (pt) 2011-12-07 2021-11-09 Allergan Inc Entrega eficiente de lípidos para o filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CA2967413C (en) 2014-11-25 2023-08-15 Allergan, Inc. Ophthalmic compositions containing omega-3 oils stabilized by antioxidants
EP3852608A4 (en) * 2018-09-21 2022-09-28 Aufbau Medical Innovations Limited COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042936C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ophthalmic use
AU1427592A (en) * 1991-02-07 1992-09-07 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
CN1129400A (zh) * 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
BRPI9816218B1 (pt) 2016-04-12
AU738781B2 (en) 2001-09-27
NO327713B1 (no) 2009-09-14
CN1249687A (zh) 2000-04-05
NZ337322A (en) 2001-05-25
ID22389A (id) 1999-10-07
IL131041A0 (en) 2001-01-28
TW527187B (en) 2003-04-11
DE69820997T3 (de) 2011-10-06
MY122237A (en) 2006-04-29
ZA982188B (en) 1998-09-17
ES2214706T3 (es) 2004-09-16
HUP0002194A2 (hu) 2000-12-28
JP2001515502A (ja) 2001-09-18
RU2197970C2 (ru) 2003-02-10
PE61899A1 (es) 1999-06-30
JP4920124B2 (ja) 2012-04-18
KR20000076330A (ko) 2000-12-26
JP2010043110A (ja) 2010-02-25
EE04091B1 (et) 2003-08-15
NO994481D0 (no) 1999-09-16
DE69820997T2 (de) 2004-12-09
EE9900410A (et) 2000-04-17
CA2280089C (en) 2009-03-03
WO1998041208A1 (en) 1998-09-24
KR100555818B1 (ko) 2006-03-03
PL335168A1 (en) 2000-04-10
CL2009001870A1 (es) 2010-01-22
BR9808016A (pt) 2000-03-08
HUP0002194A3 (en) 2012-08-28
CY2526B1 (en) 2006-02-08
DK0969846T3 (da) 2004-04-13
DK0969846T4 (da) 2010-12-20
CN1236775C (zh) 2006-01-18
ATE257385T1 (de) 2004-01-15
CZ325799A3 (cs) 2000-01-12
CZ299833B6 (cs) 2008-12-10
ES2214706T5 (es) 2011-02-02
CO4940427A1 (es) 2000-07-24
SI0969846T1 (en) 2004-06-30
EP0969846A1 (en) 2000-01-12
AR011192A1 (es) 2000-08-02
AR002194A1 (es) 1998-01-07
PT969846E (pt) 2004-05-31
CA2280089A1 (en) 1998-09-24
EP0969846B1 (en) 2004-01-07
DE69820997D1 (de) 2004-02-12
HU228896B1 (en) 2013-06-28
EP0969846B2 (en) 2010-08-25
SI0969846T2 (sl) 2010-12-31
AU7035398A (en) 1998-10-12
HK1026841A1 (en) 2000-12-29
UA63938C2 (uk) 2004-02-16
PL197509B1 (pl) 2008-04-30

Similar Documents

Publication Publication Date Title
NO994481L (no) Sammensetninger og fremgangsmaater for redusering av okulaer hypertensjon
SE9702706D0 (sv) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
CA2294812A1 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
CA2293325C (en) 8-iso-prostaglandins for glaucoma therapy
RU2004111984A (ru) Способ лечения инфекций среднего уха
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
ZA200201903B (en) Use of H1 antagonist and a safe steriod to treat eye conditions.
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
DK1395263T3 (da) 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk
WO1996016647A3 (en) Use of chloride channel blockers for reducing intraocular pressure
ES2183148T3 (es) Composiciones oftalmicas que contienen un inhibidor de anhidrasa carbonica y de la goma de xantano.
WO2002007731A3 (en) Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma
AP1754A (en) Pharmaceutical compositions based on azetidine derivatives.
WO2000038667A3 (en) Prostaglandin e agonists for treatment of glaucoma
TR200400424T4 (tr) IOP'nin kontrolü ve glokom tedavisi için 5HT2 agonistleri
ES2144744T3 (es) Composicion anti-espuma.
US6071875A (en) TGFα for the treatment of ocular hypertension and glaucoma
ECSP982443A (es) Composiciones y metodos para reducir la hipertension ocular
ATE289198T1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
JP3442168B2 (ja) ケア用品
ATE227135T1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
WO2003011299A3 (en) Treatment of ocular hypertension and glaucoma
JPH08157886A (ja) コンタクトレンズ用溶液
TH42238A (th) องค์ประกอบและวิธีการลดความดันโลหิตสูงในลูกตา

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees